Jump to the main content block

Zhao-Ting Yeh

葉昭廷 (Zhao -Ting Yeh)


LabLiver Research Center


University/NationUniversity of Southern California, USA

Tel: (03)2118800 ext. 403-8125


Research website

Research interests:

 1. Molecular virology of HBV and viral mutants. Most of the early studies focused on the molecular biology of hepatitis B virus precore and core proteins. Some recently works focused on YMDD mutants developed during prolonged anti-viral therapy. (J Virol 1990, 1991; PNAS 1993; J Hepatol 2000; Hepatology 2000; Gastroenterology 2007; Antivir Ther 2008, 2009, 2010).

2. Hepatocarcinogenesis. The goals were to search for hepatoma-related viral mutants and hepatoma-related aberrant gene transcripts or under-expressed genes, which might serve as a tumor suppressor. (Cancer Res 2000; Oncogene 2000; Oncogene 2003; Hepatology 2010, in press).

3. New models for hepatitis C virus replication. Using molecular biology approach, a cDNA named Sip-L was found capable of supporting a complete cycle of HCV infection. Also, an ex vivo system has also been developed to study clinical relevance of the in vitro findings (J Virol 2001; J Infect Dis 2006; J Viral Hepat 2009).

4. New viruses.
Searching for new human pathogenic viruses. Presently, a putative virus named NV-F has been identified (J Infect Dis 2006; J Infect Dis 2008).



Yeh CT, So M, Ng J, Yang HW, Chang ML, Lai MW, Chen TC, Lin CY, Yeh TS, Lee WC. Hepatitis B virus-DNA level and basal core promoter A1762T/G1764A mutation in liver tissue independently predict postoperative survival in hepatocellular carcinoma. Hepatology. 2010; In press.

Yeh CT. Development of HBV S gene mutants in chronic hepatitis B patients receiving nucleotide/nucleoside analogue therapy. Antivir Ther. 2010;15(3 Pt B):471-5. Review.

Yeh CT, Kuo CJ, Lai MW, Chen TC, Lin CY, Yeh TS, Lee WC. CD133-positive hepatocellular carcinoma in an area endemic for hepatitis B virus infection. BMC Cancer. 2009 Sep 11;9:324.

Cheng JC, Yeh YJ, Pai LM, Chang ML, Yeh CT. 293 cells over-expressing human ADI1 and CD81 are permissive for serum-derived hepatitis C virus infection. J Med Virol. 2009 Sep;81(9):1560-8.

Yeh CT, Hsu CW, Chen YC, Liaw YF. Withdrawal of lamivudine in HBeAg-positive chronic hepatitis B patients after achieving effective maintained virological suppression. J Clin Virol. 2009 Jun;45(2):114-8.

Chang ML, Sung KF, Sheen IS, Lin SM, Yeh CT. A liver slice culture-based ex vivo assay to predict the outcome of antiviral therapy for chronic hepatitis C. J Viral Hepat. 2009 May;16(5):359-66.

Lai MW, Huang SF, Hsu CW, Chang MH, Liaw YF, Yeh CT. Identification of nonsense mutations in hepatitis B virus S gene in patients with hepatocellular carcinoma developed after lamivudine therapy. Antivir Ther. 2009;14(2):249-61.

Yeh CT. Is the NV-F agent a novel hepatitis virus? Future Microbiol. 2009 Mar;4(2):123-5.

Lai MW, Yeh CT. The oncogenic potential of hepatitis B virus rtA181T/ surface truncation mutant. Antivir Ther. 2008;13(7):875-9.

Yeh CT, Tang JH, Hsu CW, Chen YC, Chang ML, Lin CY. Expression of hepatitis B virus nuclear core antigen in young cirrhotic patients is associated with an unfavourable long-term outcome. J Viral Hepat. 2008 Nov;15(11):839-48.

Yeh CT, Lai HY, Yeh YJ, Cheng JC. Hepatitis C virus infection in mouse hepatoma cells co-expressing human CD81 and Sip-L. Biochem Biophys Res Commun. 2008 Jul 18;372(1):157-61.

Chang ML, Hsu CW, Huang SF, Chen TC, Lin SM, Yeh CT. Dense packing of portal lymphocytes predicts favorable treatment outcome in hepatitis C. Hepatogastroenterology. 2008 Sep-Oct;55(86-87):1716-20.

Yeh CT, Hsu CW, Chang ML, Tsao ML. Impact of the novel hepatotropic viruslike agent NV-F during chronic hepatitis C virus infection. J Infect Dis. 2008 Dec 15;198(12):1742-8.

Hsu CW, Yeh CT*, Chang ML, Liaw YF. Identification of a hepatitis B virus S gene mutant in lamivudine-treated patients experiencing HBsAg seroclearance. Gastroenterology. 2007 Feb;132(2):543-50.

Sheen IS, Tsou YK, Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC, Chang ML, Yeh CT. Nuclear HBcAg and histology activity index as independent predictors of the expression of singly spliced HBV-RNA. J Viral Hepat. 2007 Jan;14(1):70-4.

Yeh CT, Chen TC, Chang ML, Hsu CW, Yeh TS, Lee WC, Huang SF, Tsai CC. Identification of NV-F virus DNA in hepatocellular carcinoma. J Med Virol. 2007 Jan;79(1):92-6.

Hsu CW, Cheng JC, Yeh CT. Quantitative assessment of serum NV-F virus DNA concentrations in samples from patients coinfected with hepatitis B or C virus. J Clin Microbiol. 2006 Sep;44(9):3130-3.

Yeh CT, Lin WP, Hsu CW, Chang ML, Lin SM, Sheen IS. Emergence and takeover of precore-stop mutant prior to exacerbation of e antigen-negative chronic hepatitis B after withdrawal of lamivudine therapy. J Med Virol. 2006 Jul;78(7):906-10.

Chang KW, Yang PY, Lai HY, Yeh TS, Chen TC, Yeh CT. Identification of a novel actin isoform in hepatocellular carcinoma. Hepatol Res. 2006 Sep;36(1):33-9.

Tsao ML, Chao CH, Yeh CT. Interaction of hepatitis C virus F protein with prefoldin 2 perturbs tubulin cytoskeleton organization. Biochem Biophys Res Commun. 2006 Sep 15;348(1):271-7.

Yeh CT, Hsu CW, Chang ML, Sheen IS, Lin SM, Lin CJ, Lin CC, Chen YC, Chen JC. A novel ex vivo assay of interferon-based suppression, to predict the outcome of antiviral therapy for hepatitis C. J Infect Dis. 2006 May 15;193(10):1365-70.

Yeh CT, Tsao ML, Lin YC, Tseng IC. Identification of a novel single-stranded DNA fragment associated with human hepatitis. J Infect Dis. 2006 Apr 15;193(8):1089-97.


Click Num: